Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 46Terminated 8Active not recruiting 4Withdrawn 3Recruiting 2No longer available 2

Sponsor Class

OTHER 7INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1

Conditions

Carcinoma, Renal Cell 3Ovarian Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Axitinib × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

MedImmune LLC

Phase 1 Active not recruiting
67 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT05256472 2025-03-06

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Akeso

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡